A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients with Active Rheumatoid Arthritis on background Methotrexate Therapy

Update Il y a 5 ans
Reference: EUCTR2010-022504-42

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of LY3009104 as assessed by the aggregate proportion of patients in the 4 mg and 8 mg dose groups who achieve an ACR20 response compared to placebo over 12 weeks in patients with active RA despite ongoing MTX therapy.


Inclusion criteria

  • Rheumatoid Arthritis